1383985-61-2

Basic information

• Product Name: (1r,4r)-6'-bromo-4-methoxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-imine hydrochloride
• Synonyms: (1r,4r)-6'-bromo-4-methoxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-imine hydrochloride;(1r,4r)-6-bromo-4-methoxyspiro[cyclohexane-1,2-inden]-1(3H)-imine hydrochloride(WXC04996)
• CAS NO: 1383985-61-2
• Molecular Formula: C₁₅H₁₈BrNO*ClH
• Molecular Weight: 344.67446
• Mol File: 1383985-61-2.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1r,4r)-6'-bromo-4-methoxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-imine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4r)-6'-bromo-4-methoxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-imine hydrochloride(1383985-61-2)
• EPA Substance Registry System: (1r,4r)-6'-bromo-4-methoxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-imine hydrochloride(1383985-61-2)

Safety Data

• Hazardous Substances Data: 1383985-61-2(Hazardous Substances Data)

Upstream product

• 1245516-72-6 (1r,4r)-6’-bromo-4-methoxyspiro(cyclohexane-1,2’-indene)-1’(3’H)-one 
• 1383985-60-1 N-((1r,4r)-5'-bromo-4-methoxyspiro[cyclohexane-1,2'-indene]-3'(1'H)-ylidene)-2-methylpropane-2-sulfinamide 
• 1245514-97-9 (1r,4r)-6’-bromo-4-hydroxyspiro(cyclohexane-1,2’-indene)-1’(3’H)-one 
• 1383985-06-5 6’-bromo-4-hydroxyspiro[cyclohexane-1,2’-inden]-1‘(3‘H)-one 
• 1245514-96-8 6^,-bromo-4H-spiro[cyclohexane-1,2'-indene]-1^,,4(3^,H)-dione 
• 14548-39-1 6-bromoindan-1-one 
• 146374-27-8 S-tert-butylsulfinimide 

Downstream Products

• 1383982-64-6 (1r,1’R,4R)-4-methoxy-5”-methyl-6’-[5-(prop-1-yn-1-yl)pyridin-3-yl]-3’H-dispiro[cyclohexane-1,2’-indene-1’2”-imidazol]-4”-amine 

Relevant articles and documents

Process Intensification and Integration Studies for the Generation of a Key Aminoimidazole Intermediate in the Synthesis of Lanabecestat

An improved synthetic procedure for the multistep synthesis of aminoimidazole 6, a key intermediate in the preparation of lanabecestat (AZD3293/LY3314814), is described. Under intensified conditions (high temperature and elevated pressure), the overall processing time and required amounts of reagents could be significantly reduced, thus potentially minimizing manufacturing costs and improving the sustainability footprint. Process integration of three sequential steps starting from ketone intermediate 2 has been attempted to set the stage for a potential multistep continuous manufacturing route. The process consists of initial formation of imine 3 by treatment of ketone 2 with ammonia and Ti(iPrO)4, cyclocondensation of 3 with thioamide 4 to form thiol 5, and aminolysis using ammonia and Zn(OAc)2, allowing the target building block 6 to be accessed in 47% overall yield.

2H-IMIDAZOL-4-AMINE COMPOUNDS AND THEIR USE AS BACE INHIBITORS

2H-imidazol-4-amine compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Αβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration methods of therapy, and pharmaceutical compositions containing such compounds. Formula (I) wherein A is -O- or -CH2-, n is 1 or 1.

Compounds and their use as BACE Inhibitors

The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.